Literature DB >> 33449503

Conditioned open-label placebo for opioid reduction after spine surgery: a randomized controlled trial.

Kelsey M Flowers1, Megan E Patton1, Valerie J Hruschak1, Kara G Fields1, Emily Schwartz1, Jose Zeballos1, James D Kang2, Rob R Edwards1, Ted J Kaptchuk3, Kristin L Schreiber1.   

Abstract

ABSTRACT: Placebo effects have traditionally involved concealment or deception. However, recent evidence suggests that placebo effects can also be elicited when prescribed transparently as "open-label placebos" (OLPs), and that the pairing of an unconditioned stimulus (eg, opioid analgesic) with a conditioned stimulus (eg, placebo pill) can lead to the conditioned stimulus alone reducing pain. In this randomized control trial, we investigated whether combining conditioning with an OLP (COLP) in the immediate postoperative period could reduce daily opioid use and postsurgical pain among patients recovering from spine surgery. Patients were randomized to COLP or treatment as usual, with both groups receiving unrestricted access to a typical opioid-based postoperative analgesic regimen. The generalized estimating equations method was used to assess the treatment effect of COLP on daily opioid consumption and pain during postoperative period from postoperative day (POD) 1 to POD 17. Patients in the COLP group consumed approximately 30% less daily morphine milligram equivalents compared with patients in the treatment as usual group during POD 1 to 17 (-14.5 daily morphine milligram equivalents; 95% CI: [-26.8, -2.2]). Daily worst pain scores were also lower in the COLP group (-1.0 point on the 10-point scale; 95% CI: [-2.0, -0.1]), although a significant difference was not detected in average daily pain between the groups (-0.8 point; 95% CI: [-1.7, 0.2]). These findings suggest that COLP may serve as a potential adjuvant analgesic therapy to decrease opioid consumption in the early postoperative period, without increasing pain.
Copyright © 2021 International Association for the Study of Pain.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33449503     DOI: 10.1097/j.pain.0000000000002185

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  5 in total

1.  How orthopedic surgeons view open label placebo pills: Ethical and effective, but opposed to personal use.

Authors:  Michael H Bernstein; Maayan Rosenfield; Nathaniel Fuchs; Molly Magill; Charlotte R Blease; Francesca L Beaudoin; Josiah D Rich; Karolina Wartolowska; Richard M Terek
Journal:  J Psychosom Res       Date:  2021-10-05       Impact factor: 3.006

2.  Can the Open Label Placebo Rationale Be Optimized?

Authors:  Uwe Heiss; Maayan Rosenfield; Michael H Bernstein
Journal:  Front Pain Res (Lausanne)       Date:  2021-09-30

3.  The Use of Conditioning Open-Label Placebo in Opioid Dose Reduction: A Case Report and Literature Review.

Authors:  Maria A Estudillo-Guerra; Ines Mesia-Toledo; Jeffrey C Schneider; Leon Morales-Quezada
Journal:  Front Pain Res (Lausanne)       Date:  2021-07-12

4.  Editorial: Placebo Effect in Pain and Pain Treatment.

Authors:  Michael H Bernstein; Charlotte Blease; Lene Vase
Journal:  Front Pain Res (Lausanne)       Date:  2022-03-29

5.  Conditioning to Enhance the Effects of Repetitive Transcranial Magnetic Stimulation on Experimental Pain in Healthy Volunteers.

Authors:  Léa Proulx-Bégin; Alberto Herrero Babiloni; Sabrina Bouferguene; Mathieu Roy; Gilles J Lavigne; Caroline Arbour; Louis De Beaumont
Journal:  Front Psychiatry       Date:  2022-02-22       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.